© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org
Case Report
Effective therapeutic use of rituximab in refractory Wegener's granulomatosis
1 Queen Elizabeth Hospital, Department of Nephrology, Birmingham, 2 Birmingham University, Division of Immunity and Infection, Birmingham, UK
Correspondence and offprint requests to: Professor Caroline O. Savage, Division of Immunity and Infection, University of Birmingham, B15 2TT
Keywords: ANCA; Immunosuppressive agents; Monoclonal antibody; Therapy; Vasculitis; Wegener
| The first 150 words of the full text of this article appear below. |
 |
Introduction |
|---|
Wegener's granulomatosis (WG) is a chronic, multisystem disease, characterized by a small vessel vasculitis. Whilst it previously carried a high early mortality (80% in 2 years) [1], the advent of cyclophosphamide therapy for the induction of remission has reduced this greatly. Despite the use of other immunosuppressive agents, including methotrexate, azathioprine and mycophenolate mofetil, to maintain remission, relapse often occurs – with many patients requiring further courses of cyclophosphamide over many years.
Despite its success at remission induction, cyclophosphamide therapy comes at a heavy price, with increased rates of infection resulting in significant morbidity and mortality, and dose-related increases in rates of haematological and solid organ malignancies [2]. As a result, alternative therapeutic strategies, for example directed against cytokines such as tumour necrosis factor (TNF), are also being tested with some success [3], but these also carry significant risks of opportunistic infection, especially with
|
Case |
|---|
|
Discussion |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. C. Fervenza, S. Sethi, and U. Specks Idiopathic Membranous Nephropathy: Diagnosis and Treatment Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 905 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii2 - iii22. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Niedermeier, R. Eming, M. Pfutze, C. R. Neumann, C. Happel, K. Reich, and M. Hertl Clinical Response of Severe Mechanobullous Epidermolysis Bullosa Acquisita to Combined Treatment With Immunoadsorption and Rituximab (Anti-CD20 Monoclonal Antibodies) Arch Dermatol, February 1, 2007; 143(2): 192 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. Wong Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence? Nephrol. Dial. Transplant., January 1, 2007; 22(1): 32 - 36. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Stasi, E. Stipa, G. Del Poeta, S. Amadori, A. C. Newland, and D. Provan Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab Rheumatology, November 1, 2006; 45(11): 1432 - 1436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Morgan, L. Harper, J. Williams, and C. Savage Anti-Neutrophil Cytoplasm-Associated Glomerulonephritis J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1224 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Frankel, G. P. Cosgrove, A. Fischer, R. T. Meehan, and K. K. Brown Update in the diagnosis and management of pulmonary vasculitis. Chest, February 1, 2006; 129(2): 452 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Keogh, S. R. Ytterberg, F. C. Fervenza, K. A. Carlson, D. R. Schroeder, and U. Specks Rituximab for Refractory Wegener's Granulomatosis: Report of a Prospective, Open-Label Pilot Trial Am. J. Respir. Crit. Care Med., January 15, 2006; 173(2): 180 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C M G Cheung, P I Murray, and C O S Savage Successful treatment of Wegener's granulomatosis associated scleritis with rituximab Br J Ophthalmol, November 1, 2005; 89(11): 1542 - 1542. [Full Text] [PDF]
|
|
|
|
|
|
C. Bachmeyer, J.-F. Cadranel, and R. Demontis Rituximab is an alternative in a case of contra-indication of cyclophosphamide in Wegener's granulomatosis Nephrol. Dial. Transplant., June 1, 2005; 20(6): 1274 - 1274. [Full Text] [PDF]
|
|